Literature DB >> 3861206

Inhibition of monoamine oxidase in 5-hydroxytryptaminergic neurones by substituted p-aminophenylalkylamines.

A L Ask, I Fagervall, L Florvall, S B Ross, S Ytterborn.   

Abstract

A series of substituted p-aminophenethylamines and some related compounds were examined with regards to the inhibition of monoamine oxidase (MAO) in vivo inside and outside 5-hydroxytryptaminergic neurones in the rat hypothalamus. This was recorded as the protection against the irreversible inhibition of MAO produced by phenelzine by determining the remaining deaminating activity in the absence and presence of citalopram using a low (0.1 microM) concentration of [14C]-5-hydroxytryptamine (5-HT) as substrate. Some of the phenethylamines were much more potent inside than outside the 5-hydroxytryptaminergic neurones. This neuronal selectivity was antagonized by pretreatment of the rats with norzimeldine, a 5-HT uptake inhibitor, which indicates that these compounds are accumulated in the 5-HT nerve terminals by the 5-HT pump. Selectivity was obtained for compounds with dimethyl, monomethyl or unsubstituted p-amino groups. An isopropyl group appears to substitute for the dimethylamino group but with considerably lower potency. Compounds with 2-substitution showed selectivity for aminergic neurones and this effect decreased with increased size of the substituent. The 2,6-dichloro derivative FLA 365 had, however, no neuronal selective action but was a potent MAO inhibitor. Substitutions in the 3- and 5-positions decreased both potency and selectivity. Prolongation of the side chain with one methylene group abolished the preference for the MAO in 5-hydroxytryptaminergic neurones although the MAO inhibitory potency remained. The selectivity disappeared by increasing the alpha-substituent to an ethyl group but remained for the alpha,alpha-dimethyl substituted derivatives. It is concluded that compounds which are (1) transported by the 5-HT pump and (2) potent reversible MAO-A inhibitors produce pronounced inhibition of MAO in 5-hydroxytryptaminergic neurones.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3861206      PMCID: PMC1916528          DOI: 10.1111/j.1476-5381.1985.tb10564.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  Selective monoamine oxidase inhibitors. 1. Compounds related to 4-aminophenethylamine.

Authors:  L Florvall; A L Ask; S O Ogren; S B Ross
Journal:  J Med Chem       Date:  1978-01       Impact factor: 7.446

2.  Evidence for a selective inhibition by FLA 336(+) of the monoamine oxidase in serotonergic neurones in the rat brain.

Authors:  A L Ask; I Fagervall; S B Ross
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1982-10

3.  A new approach to the assessment of the potency of reversible monoamine oxidase inhibitors in vivo, and its application to (+)-amphetamine, p-methoxyamphetamine and harmaline.

Authors:  A L Green; M A El Hait
Journal:  Biochem Pharmacol       Date:  1980-10-15       Impact factor: 5.858

Review 4.  Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity.

Authors:  J Hyttel
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1982       Impact factor: 5.067

5.  Substrate- and stereoselective inhibitor of human brain monoamine oxidase by 4-dimethylamino-alpha, 2-dimethylphenethylamine (FLA 336).

Authors:  C J Fowler; L Oreland
Journal:  J Pharm Pharmacol       Date:  1981-06       Impact factor: 3.765

6.  Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat brain.

Authors:  A L Ask; I Fagervall; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

7.  (+)-4-Dimethylamino-2,alpha-dimethylphenethylamine (FLA 336(+)), a selective inhibitor of the A form of monoamine oxidase in the rat brain.

Authors:  A L Ask; K Högberg; L Schmidt; H Kiessling; S B Ross
Journal:  Biochem Pharmacol       Date:  1982-04-01       Impact factor: 5.858

8.  Selective inhibition of the A form of monoamine oxidase by 4-dimethylamino-alpha-methylphenylalkylamine derivatives in the rat.

Authors:  A L Ask; W Hellström; S Norrman; S O Ogren; S B Ross
Journal:  Neuropharmacology       Date:  1982-04       Impact factor: 5.250

9.  Structural requirements for uptake into serotoninergic neurones.

Authors:  S B Ross; A L Ask
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980-04

10.  Intra- and extraneuronal monoamine oxidase.

Authors:  C J Fowler; O Magnusson; S B Ross
Journal:  Blood Vessels       Date:  1984
  10 in total
  6 in total

1.  Charge-transfer interactions in the inhibition of MAO-A by phenylisopropylamines--a QSAR study.

Authors:  Gabriel Vallejos; Marcos Caroli Rezende; Bruce K Cassels
Journal:  J Comput Aided Mol Des       Date:  2002-02       Impact factor: 3.686

Review 2.  Predicting monoamine oxidase inhibitory activity through ligand-based models.

Authors:  Santiago Vilar; Giulio Ferino; Elias Quezada; Lourdes Santana; Carol Friedman
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

3.  Inhibition of 5-hydroxytryptamine accumulation and deamination by substituted phenylalkylamines in hypothalamic synaptosomes from normal and reserpine-pretreated rats.

Authors:  A L Ask; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-12       Impact factor: 3.000

4.  Selective inhibition by 4,alpha-dimethyl-m-tyramine (H77/77) and 4-methyl-alpha-ethyl-m-tyramine (H75/12) of the monoamine oxidase within serotonergic and noradrenergic neurons in the rat brain.

Authors:  I Fagervall; D Kelder; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

5.  Release of 3H-5-hydroxytryptamine by amiflamine and related phenylalkylamines from rat occipital cortex slices.

Authors:  A L Ask; I Fagervall; R B Huang; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

Review 6.  Amphetamine Derivatives as Monoamine Oxidase Inhibitors.

Authors:  Miguel Reyes-Parada; Patricio Iturriaga-Vasquez; Bruce K Cassels
Journal:  Front Pharmacol       Date:  2020-01-23       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.